BioCentury | Dec 6, 2019
Targets & Mechanisms

Emerging immuno-oncology mechanisms at ASH 2019

Researchers are finding new ways to monitor the immune system in hematologic diseases that could have implications for optimizing immuno-oncology therapies, according to BioCentury’s analysis of emerging targets at ASH 2019. In abstracts released ahead...
BioCentury | Sep 5, 2013
Distillery Therapeutics

Indication: Neurology

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology Adenosine monophosphate deaminase 2 (AMPD2) In vitro and genetic...
...early onset PCH and their families identified a subset in the cohort with mutations in AMPD2...
...cell viability. Next steps could include developing animal models of PCH based on mutations in Ampd2...
Items per page:
1 - 2 of 2